SCHEMBL7216170

SCHEMBL7216170

CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCC(=O)N[C@H](C(=O)O)C(C)OP(=O)(O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 2/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
CNR2 P34972 4/20 0.56
ALDH1A1 P00352 2/20 0.56
BLM P54132 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
KCNK3 O14649 1/20 0.56
THRB P10828 1/20 0.56
LPAR3 Q9UBY5 1/20 0.54
CNR1 P21554 1/20 0.51
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
FAAH O00519 1/20 0.50
USP2 O75604 1/20 0.50
POLB P06746 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
APEX1 P27695 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7216068 1.00 SLC6A5 (0.62) SLC6A5SMN1; SMN2CNR2ALDH1A1BLM
SCHEMBL7216171 1.00 SLC6A5 (0.62) SLC6A5SMN1; SMN2CNR2ALDH1A1BLM
SCHEMBL7216064 1.00 SLC6A5 (0.62) SLC6A5SMN1; SMN2CNR2ALDH1A1BLM
SCHEMBL7217356 0.92 ALDH1A1 (0.54) SLC6A5SMN1; SMN2CNR2ALDH1A1BLM
SCHEMBL7217354 0.92 ALDH1A1 (0.54) SLC6A5SMN1; SMN2CNR2ALDH1A1BLM
SCHEMBL7217351 0.92 ALDH1A1 (0.54) SLC6A5SMN1; SMN2CNR2ALDH1A1BLM
SCHEMBL7212463 0.90 ALDH1A1 (0.52) SLC6A5SMN1; SMN2CNR2ALDH1A1BLM
SCHEMBL7212459 0.90 ALDH1A1 (0.52) SLC6A5SMN1; SMN2CNR2ALDH1A1BLM
SCHEMBL7212455 0.90 ALDH1A1 (0.52) SLC6A5SMN1; SMN2CNR2ALDH1A1BLM
SCHEMBL7212475 0.90 ALDH1A1 (0.52) SLC6A5SMN1; SMN2CNR2ALDH1A1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161436-B1 Polyunsaturated fatty acid derivatives and their use in the treatment of cancer ARDENIA INVESTMENTS LTD (GI) 2003-06-25 EP disclosed
US-6403554-B2 Polyunsaturated fatty acid derivatives and their use ARDENIA INVESTMENTS LTD. (GI) 2002-06-11 US disclosed
US-20010037032-A1 Polyunsaturated fatty acid derivatives and their use OASMIA PHARMACEUTICAL AB (SE) 2001-11-01 US disclosed
US-6274747-B1 COMPOUNDS CONTAINING A PHOSPHATE GROUP AND SECONDARY AMIDE GROUP; ANTICANCER AGENTS ARDENIA INVESTMENTS LTD. (GI) 2001-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010037032-A1 Polyunsaturated fatty acid derivatives and their use RXRA, RXRB, LPAR2 SLC6A5 2332/4885SMN1; SMN2 2834/4885CNR2 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.